Rad51C Inhibitors

Rad51C inhibitors, as a class, primarily consist of chemicals that can indirectly influence the function of RAD51C by targeting associated proteins or processes in the homologous recombination repair (HRR) pathway. One prevalent approach involves the use of PARP inhibitors, like Olaparib, Niraparib, Rucaparib, and Talazoparib. These compounds inhibit PARP1, causing DNA single-strand breaks to persist and subsequently challenge the HRR machinery, to which RAD51C contributes. Another strategy is the use of RAD51 inhibitors, such as B02 and RI-1. These directly hinder RAD51, a protein closely interlinked with RAD51C, thereby impeding the HRR process.

Furthermore, there are inhibitors that target key enzymes in the DNA damage response, such as ATR, ATM, and DNA-PKcs, using compounds like VE-821, KU-60019, and NU7441 respectively. These inhibitors affect the early stages of the HRR pathway, which in turn, can impact the efficiency and function of RAD51C. In addition, by targeting proteins like MRE11 with Mirin or WEE1 kinase with MK-1775, the HRR process is further compromised. Collectively, while not directly targeting RAD51C, these compounds exert their inhibitory effects by either disrupting the function of associated proteins or by overwhelming the HRR pathway, influencing the role and function of RAD51C in the process.